Abstract：Abstract: To evaluate the consistency of atorvastatin by urine proteomics, rat models were established by intragastric administration of atorvastatin tablets from two companies (A and B). Urine samples were collected from rats before and after intragastric administration. Urine proteins were profiled using liquid chromatogra-phy coupled with tandem mass spectrometry (LC-MS/MS), and the biological pathways of the differential pro-teins were analyzed by DAVID database. The differential proteins were selected by comparing protein pro-files before and after intragastric administration. A total of 116 differential proteins were identified in group A and 66 differential proteins in group B. Among them, 24 proteins appeared in both groups. These diffe-rential proteins were found to be involved in biological pathways such as cell adhesion, negative regulation of endopeptidase activity and proteolysis. Small differences between the two kinds of atorvastatin could be- detected in urinary proteins, which confirmed the sensitivity of urinary protein analysis and suggested that urine proteomics has great potential for the drug consistency evaluation.
引用本文:
赵晨阳, 陈昱臻, 付晓越, 侯芙芳, 高友鹤. 利用尿液蛋白质组学对阿托伐他汀进行药物一致性评价[J]. 生命科学研究, 2022, 26(5): 424-432. ZHAO Chen-yang, CHEN Yu-zhen, FU Xiao-yue, HOU Fu-fang, GAO You-he. Consistency Evaluation of Atorvastatin by Urine Proteomics. Life Science Research, 2022, 26(5): 424-432.
